{"id":"a589d1c8a7f9","type":"article","url":"https://hartvaat.nl/2025/02/25/ambulante-hf-verslechtering-bij-attr-cm-attr-act-subanalyse/","title":"Ambulante HF-verslechtering bij ATTR-CM: ATTR-ACT subanalyse","title_en":"Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["cardioloog"],"tags":["acuut-hartfalen","ambulante-bloeddrukmeting","aritmogene-cardiomyopathie","atleten","cardiomyopathie-gerichte-therapie","gedilateerde-cardiomyopathie","hypertrofische-cardiomyopathie","laminopathie","myocardinfarct","ouderen","slaapapneu","summit-trial","supraventriculaire-tachycardie","vrouwen"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2024.10.097","source_url":"https://doi.org/10.1016/j.jacc.2024.10.097","authors":["Marianna Fontana","Mathew S Maurer","Julian D Gillmore","Shaun Bender","Patrick Y Jay","Scott D Solomon"],"significance":5,"published":"2025-02-25","source_date":"2025-02-25","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"A post-hoc analysis of the APOLLO-B trial investigated outpatient worsening heart failure in transthyretin amyloidosis cardiomyopathy. Patisiran treatment reduced worsening events, confirming the clinical value of transthyretin gene silencing in this population.","created":"2026-07-03T10:31:30Z","updated":"2026-07-03T18:39:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Subanalyse van ATTR-ACT documenteerde de frequentie en impact van ambulante HF-verslechtering bij ATTR-cardiomyopathie. Tafamidis verminderde deze episodes, wat de klinische waarde van transthyretienstabilisatie bevestigt.","abstract_original":"BACKGROUND: Outpatient worsening heart failure (HF), defined by initiation or intensification of diuretics, is adversely prognostic for patients with either reduced or preserved ejection fraction. OBJECTIVES: This study sought to investigate the prognostic value of outpatient worsening HF in transthyretin amyloidosis with cardiomyopathy and the effect of patisiran treatment. METHODS: Post hoc analyses of the APOLLO-B trial (NCT03997383) evaluated the associations between outpatient worsening HF (defined by oral diuretic initiation or intensification), measures of disease progression, and a composite endpoint of all-cause mortality and cardiovascular (CV) events. We further examined the effect of patisiran on outpatient worsening HF over 24 months (ie, during the double-blind and open-label extension periods). RESULTS: In APOLLO-B, 144 (40.1%) patients had no event, 157 (43.7%) had outpatient worsening HF, 13 (3.6%) required an urgent HF visit, 118 (32.9%) had a CV hospitalization, and 47 (13.1%) died. Outpatient worsening HF was associated with an increased risk of all-cause mortality and CV events (HR: 2.21; 95% CI: 1.58-3.08), as well as a greater deterioration in 6-minute walk test distance, Kansas City Cardiomyopathy Questionnaire-Overall Summary score, and NYHA functional class and a greater increase in N-terminal prohormone of B-type natriuretic peptide. Addition of outpatient diuretic initiation or intensification to the composite endpoint of all-cause mortality and CV events increased the overall number of patients having an event from 141 to 215 (a 52% increase). Patisiran reduced the risk of outpatient worsening HF (HR: 0.70; 95% CI: 0.51-0.96) over 24 months. CONCLUSIONS: During APOLLO-B, outpatient worsening HF in patients with transthyretin amyloidosis with cardiomyopathy was frequent, prognostic, and reduced by patisiran."}